Evidence map›Paper›PMID 38734314›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2024

"Click" amphotericin B in prodrug nanoformulations for enhanced systemic fungemia treatment.

Dandan Guo, Changying Shi, Liye Suo, Xiaotian Ji, Hao Yue, Dekai Yuan, Juntao Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. A Rare Case of Cutaneous Mucormycosis byClinical case reports · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dandan GuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Changying ShiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Liye SuoDepartment of Pathology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Xiaotian JiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Hao YueDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Dekai YuanDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Juntao LuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Department of Surgery, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Sepsis Interdisciplinary Research Center (SIRC), State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: luoj@upstate.edu.

Funding

An innovative hemoperfusion nanotrap for sepsis treatment.R01GM130941 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2018 to 2021
$1.5M
Rational Design and High throughput synthesis of nanocarriers for efficient drug deliveryR21EB019607 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2015 to 2016
$453k
NIBIB NIH HHS R21 EB019607NIGMS NIH HHS R01 GM130941
6 · The paper itself

Abstract

Severe nephrotoxicity and infusion-related side effects pose significant obstacles to the clinical application of Amphotericin B (AmB) in life-threatening systemic fungal infections. In pursuit of a cost-effective and safe formulation, we have introduced multiple phenylboronic acid (PBA) moieties onto a linear dendritic telodendrimer (TD) scaffold, enabling effective AmB conjugation via boronate chemistry through a rapid, high yield, catalysis-free and dialysis-free "Click" drug loading process. Optimized AmB-TD prodrugs self-assemble into monodispersed micelles characterized by small particle sizes and neutral surface charges. AmB prodrugs sustain drug release in circulation, which is accelerated in response to the acidic pH and Reactive Oxygen Species (ROS) in the infection and inflammation. Prodrugs mitigate the AmB aggregation status, reduce cytotoxicity and hemolytic activity compared to Fungizone®, and demonstrate superior antifungal activity to AmBisome®. AmB-PEG

Indexed as

Amphotericin BAntifungal AgentsFungemiaProdrugsAnimalsCandida albicansClick ChemistryDrug LiberationFemaleHumansMiceMicellesNanoparticlesPolyethylene GlycolsAmphotericin BAntifungal AgentsMicellesPolyethylene GlycolsProdrugsAmphotericin B prodrugClick boronate chemistryImmunocompromised fungal infectionpH-/ROS-responsive releaseReduced nephrotoxicityTelodendrimer nanoformulation

Identifiers

PMID38734314
PMCPMC11923797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.